MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

Published:2008-10-18 Issue:4 Volume:27 Page:379-386
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Dreicer R.,Stadler W. M.,Ahmann F. R.,Whiteside T.,Bizouarne N.,Acres B.,Limacher J.-M.,Squiban P.,Pantuck A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-008-9187-3.pdf

Reference26 articles.

1. Kupelian P, Buchsbaum J, Patel C et al (2002) Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 52:704–711 doi: 10.1016/S0360-3016(01)02778-X

2. Amling C, Blute M, Bergstralh E, Seay T, Slezak J, Zincke H (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164:101–105 doi: 10.1016/S0022-5347(05)67457-5

3. Pound C, Partin A, Epstein J, Walsh P (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 24:395–406 doi: 10.1016/S0094-0143(05)70386-4

4. Keating N, O’Malley A, Smith M (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448–4456 doi: 10.1200/JCO.2006.06.2497

5. Loblaw DA, Virgo KS, Nam R et al (2007) Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 25(12):1596–1605 doi: 10.1200/JCO.2006.10.1949

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy;Journal of Cancer;2024

2. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases;eBioMedicine;2023-04

3. Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention;Cancer Prevention Research;2023-03-31

4. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC);Journal for ImmunoTherapy of Cancer;2023-03

5. Armored modified vaccinia Ankara in cancer immunotherapy;Viral Vectors in Cancer Immunotherapy;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3